0001193805-24-000364.txt : 20240314 0001193805-24-000364.hdr.sgml : 20240314 20240314090502 ACCESSION NUMBER: 0001193805-24-000364 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240307 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240314 DATE AS OF CHANGE: 20240314 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arcturus Therapeutics Holdings Inc. CENTRAL INDEX KEY: 0001768224 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38942 FILM NUMBER: 24748083 BUSINESS ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8589002660 MAIL ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K/A 1 e619365_8ka-arct.htm
true 0001768224 0001768224 2024-03-07 2024-03-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares




Washington, D.C. 20549



Amendment No. 1



Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): March 7, 2024



(Exact name of registrant as specified in its charter)


Delaware   001-38942   32-0595345
(State or other jurisdiction
of incorporation)
File Number)
  (I.R.S. Employer
Identification No.)


10628 Science Center Drive, Suite 250

San DiegoCalifornia 92121 

(Address of principal executive offices)


Registrant’s telephone number, including area code: (858) 900-2660


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class  



  Name of each exchange
on which registered
Common stock, par value $0.001 per share   ARCT   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company 


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Explanatory Note


Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”) is filing this Amendment No. 1 on Form 8-K/A to amend certain statements made in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on March 7, 2024, as described further in Item 2.02 below.


Item 2.02. Results of Operations and Financial Condition


On March 7, 2024, the Company issued a press release announcing its financial results for fiscal year ended December 31, 2023 (the “Press Release”).


Subsequent to the issuance of this Press Release, and during the completion of the Company’s fiscal year-end audit, non-cash revenue adjustments were made resulting in a change to the final financial statements for the fourth quarter and fiscal year 2023. As it relates to the Consolidated Statement of Operations and Comprehensive Income (Loss), the changes affected the fiscal fourth quarter only and resulted in a decrease in collaboration revenue from $160.9 million to $157.7 million for the fiscal year-end and $28.2 million to $25.0 for the fiscal fourth quarter 2023. This $3.2 million adjustment resulted in an updated net loss of $29.7 million, or $1.12 per share, and $11.7 million, or $0.44 per share, for the fiscal year end and fourth quarter end 2023, respectively.


The Consolidated Balance Sheet as of fiscal year end December 31, 2023 was adjusted to reflect an increase in deferred revenue by $3.2 million offset by a decease to stockholders’ equity. The Company’s cash, cash equivalents, and restricted cash at December 31, 2023, and its statement in the Press Release regarding its cash runway expectations, are not affected by these adjustments.


The Company’s Annual Report on the Form 10-K for fiscal year ended December 31, 2023 has been filed with the SEC on March [14], 2023.


In accordance with General Instructions B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K/A shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.


Cautionary Note Regarding Forward-Looking Statements


This Current Report on Form 8-K/A and the Press Release contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this Current Report on Form 8-K/A and the Press Release, are forward-looking statements, including those regarding cash and cash runway, strategy, future operations, the likelihood of success of the Company’s pipeline (including ARCT-032 and ARCT-810) and partnered programs (including the COVID-19 and flu programs partnered with CSL Seqirus), the likelihood that preclinical or clinical data will be predictive of future clinical results, including that the results from Kostaive® (or ARCT-154) will be predictive of results for updated versions of the vaccine, the potential commercial launch of Kostaive®, the continued advancement ARCT-032 or its potential as a treatment for any of the CF population, the continued advancement of ARCT-810, the anticipated timing and sharing of clinical data including for the Company’s ARCT-810 Phase 2 study and the ARCT-032 Phase 1b study, the continued efforts for our vaccine discovery programs for lyme disease or gonorrhea, the potential of the Company’s platform technology to be meaningfully differentiated from other technologies, the continued progress of the LUNAR-FLU program, the ability to enroll participants in clinical studies including the Company’s ARCT-810 and ARCT-032 programs, the likelihood and timing of commercial activities for the Company’s LUNAR-COVID program, the likelihood that a patent will issue from any patent application, the likelihood or timing of collection of accounts receivables including expected payments from CSL, its current cash position and expected cash burn and runway, and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading "Risk Factors" in Arcturus’ most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC’s website at www.sec.gov. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. 





Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.


Exhibit No.   Description of Exhibit
104   Cover Page to this Current Report on Form 8-K in Inline XBRL







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Arcturus Therapeutics Holdings Inc.
Date: March 14, 2024  
  By: /s/ Joseph E. Payne
  Name:  Joseph E. Payne
  Title: Chief Executive Officer




EX-101.SCH 2 arct-20240307.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 arct-20240307_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 arct-20240307_pre.xml XBRL PRESENTATION FILE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Mar. 07, 2024
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”) is filing this Amendment No. 1 on Form 8-K/A to amend certain statements made in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on March 7, 2024, as described further in Item 2.02 below.
Document Period End Date Mar. 07, 2024
Entity File Number 001-38942
Entity Central Index Key 0001768224
Entity Tax Identification Number 32-0595345
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 10628 Science Center Drive
Entity Address, Address Line Two  Suite 250
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 900-2660
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol ARCT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://arcturusrx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports arct-20240307.xsd arct-20240307_lab.xml arct-20240307_pre.xml e619365_8ka-arct.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "e619365_8ka-arct.htm": { "nsprefix": "ARCT", "nsuri": "http://arcturusrx.com/20240307", "dts": { "schema": { "local": [ "arct-20240307.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "arct-20240307_lab.xml" ] }, "presentationLink": { "local": [ "arct-20240307_pre.xml" ] }, "inline": { "local": [ "e619365_8ka-arct.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://arcturusrx.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "e619365_8ka-arct.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "e619365_8ka-arct.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://arcturusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001193805-24-000364-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193805-24-000364-xbrl.zip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iso4217:USD shares iso4217:USD shares true 0001768224 8-K/A 2024-03-07 ARCTURUS THERAPEUTICS HOLDINGS INC. DE 001-38942 32-0595345 10628 Science Center Drive  Suite 250 San Diego CA 92121 (858) 900-2660 false false false false Common stock, par value $0.001 per share ARCT NASDAQ false Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”) is filing this Amendment No. 1 on Form 8-K/A to amend certain statements made in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on March 7, 2024, as described further in Item 2.02 below.